JP7132848B2 - 癌の治療のための合理的併用療法 - Google Patents

癌の治療のための合理的併用療法 Download PDF

Info

Publication number
JP7132848B2
JP7132848B2 JP2018536719A JP2018536719A JP7132848B2 JP 7132848 B2 JP7132848 B2 JP 7132848B2 JP 2018536719 A JP2018536719 A JP 2018536719A JP 2018536719 A JP2018536719 A JP 2018536719A JP 7132848 B2 JP7132848 B2 JP 7132848B2
Authority
JP
Japan
Prior art keywords
cancer
administered
administration
hsp90
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018536719A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537519A (ja
JP2018537519A5 (enExample
Inventor
ガブリエラ チオシス，
トニー タルドーン，
リザ シュレスタ，
ジョン コーレン，
エリカ エム． ゴメス－ダガマ，
アナ ロディナ，
Original Assignee
メモリアル スローン ケタリング キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2018537519A publication Critical patent/JP2018537519A/ja
Publication of JP2018537519A5 publication Critical patent/JP2018537519A5/ja
Application granted granted Critical
Publication of JP7132848B2 publication Critical patent/JP7132848B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018536719A 2015-10-05 2016-10-05 癌の治療のための合理的併用療法 Active JP7132848B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562237470P 2015-10-05 2015-10-05
US62/237,470 2015-10-05
PCT/US2016/055594 WO2017062520A1 (en) 2015-10-05 2016-10-05 Rational combination therapy for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2018537519A JP2018537519A (ja) 2018-12-20
JP2018537519A5 JP2018537519A5 (enExample) 2019-11-28
JP7132848B2 true JP7132848B2 (ja) 2022-09-07

Family

ID=57145064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018536719A Active JP7132848B2 (ja) 2015-10-05 2016-10-05 癌の治療のための合理的併用療法

Country Status (14)

Country Link
US (1) US20180280397A1 (enExample)
EP (1) EP3359196B1 (enExample)
JP (1) JP7132848B2 (enExample)
KR (1) KR20180058824A (enExample)
CN (1) CN108472376A (enExample)
AU (1) AU2016336351A1 (enExample)
BR (1) BR112018006572A2 (enExample)
CA (1) CA3000851A1 (enExample)
EA (1) EA201890623A1 (enExample)
IL (1) IL258494A (enExample)
MA (1) MA47474A (enExample)
MX (1) MX2018004112A (enExample)
TW (1) TW201722422A (enExample)
WO (1) WO2017062520A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014386214B2 (en) 2013-12-23 2020-05-21 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
CN110090303B (zh) * 2019-05-07 2022-09-16 浙江大学 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途
CN112641949A (zh) * 2021-01-11 2021-04-13 深圳市人民医院(深圳市呼吸疾病研究所) 一种含有pi3k抑制剂的药物组合物及其应用
US20240371465A1 (en) * 2023-05-02 2024-11-07 National Central University Method, system, and computer readable medium for post-translational modifications detection
CN116813622B (zh) * 2023-05-19 2026-02-03 中国科学院基础医学与肿瘤研究所(筹) 一种基于分子伴侣hsp90介导的靶向降解gpx4的嵌合体及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1337275A4 (en) 2000-11-02 2007-05-09 Sloan Kettering Inst Cancer METHOD FOR ENHANCING THE EFFICACY OF CYTOTOXIC AGENTS USING HSP 90 INHIBITORS
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
JP5599610B2 (ja) 2006-06-30 2014-10-01 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０の阻害による神経変性疾患の処置
NZ598262A (en) 2009-08-17 2014-05-30 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
WO2011044394A1 (en) 2009-10-07 2011-04-14 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
EP2694506B1 (en) 2011-04-05 2017-09-20 Sloan-kettering Institute For Cancer Research Hsp90 inhibitors
EP2694505B1 (en) 2011-04-05 2022-04-27 Sloan-kettering Institute For Cancer Research Hsp90 inhibitors
CA2841069C (en) 2011-07-08 2021-11-23 Sloan-Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
EA201690406A1 (ru) 2013-08-16 2016-08-31 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Селективные ингибиторы grp94 и способы их применения
EA201692155A1 (ru) 2014-05-13 2017-04-28 Мемориал Слоун-Кеттеринг Кэнсэ Сентр МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Blood (2007) vol.110, issue 11, 1399
Cancer Chemother. Pharmacol. (2012) vol.69, issue 4, p.1089-1097
Cancer Res. (2003) vol.63, issue 9, p.2139-2144

Also Published As

Publication number Publication date
IL258494A (en) 2018-05-31
KR20180058824A (ko) 2018-06-01
TW201722422A (zh) 2017-07-01
EP3359196B1 (en) 2022-03-16
CN108472376A (zh) 2018-08-31
US20180280397A1 (en) 2018-10-04
MA47474A (fr) 2019-12-25
MX2018004112A (es) 2018-06-20
JP2018537519A (ja) 2018-12-20
EP3359196A1 (en) 2018-08-15
BR112018006572A2 (pt) 2018-10-09
WO2017062520A1 (en) 2017-04-13
CA3000851A1 (en) 2017-04-13
AU2016336351A1 (en) 2018-05-10
EA201890623A1 (ru) 2018-09-28

Similar Documents

Publication Publication Date Title
US20230330243A1 (en) Combination of antibody-drug conjugate and atr inhibitor
US20230256110A1 (en) Combination of antibody-drug conjugate and atm inhibitor
Muñoz et al. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists
RU2665949C2 (ru) Селективность в отношении мутантных форм и комбинации соединения, представляющего собой ингибитор фосфоинозитид-3-киназы, и химиотерапевтических агентов для лечения рака
Mortensen et al. Overcoming limitations of cisplatin therapy by additional treatment with the HSP90 inhibitor onalespib
Piao et al. Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC
EP3359196B1 (en) Rational combination therapy for the treatment of cancer
BR112017015576A2 (en) method for cancer treatment, article, method for monitoring, method for optimizing therapeutic efficacy, method for identifying a biomarker, use, therapeutic combination, combination for use and product
Bansal et al. Darinaparsin inhibits prostate tumor–initiating cells and Du145 xenografts and is an inhibitor of Hedgehog signaling
WO2020132259A1 (en) Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a)
WO2010042504A1 (en) Methods of inhibiting the interaction between s100 and the receptor for advanced glycation end-products
Liu et al. SY-707, an ALK/FAK/IGF1R inhibitor, suppresses growth and metastasis of breast cancer cells: SY-707 is an ALK/FAK/IGF1R inhibitor
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
Tao et al. ERBB3 blockade sensitizes HCC to regorafenib after first-line TKI resistance by inhibiting HIF1A-ABCB1 signaling
US9566334B2 (en) Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
Lu et al. Combined treatment with cetuximab and STA9090 has synergistic anticancer effects on human non-small cell lung cancer: Combined treatment with cetuximab and STA9090 in NSCLC
Wang et al. Multi-kinase targeted therapy as a promising treatment strategy for ovarian tumors expressing sfRon receptor
HK1259690A1 (en) Rational combination therapy for the treatment of cancer
HK1259690B (en) Rational combination therapy for the treatment of cancer
US20250099426A1 (en) Indolium Compounds for Treating Cancer
Gu et al. 2β-methoxy-2-deethoxyphantomolin synergistically enhances epirubicin effect against triple-negative breast cancer via targeted inhibition of AKT and HR pathways
US12611405B2 (en) Agent that increases the expression of the BCL2-associated agonist of cell death for the treatment of cancer
CN121969391A (zh) 上调p53蛋白表达或激活p53功能的药物与DNA烷化剂联用治疗癌症
WO2025082484A1 (zh) 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者
GB2643430A (en) Nuclear transport inhibitors for anti-cancer combination therapy

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220803

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220826

R150 Certificate of patent or registration of utility model

Ref document number: 7132848

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150